Will further clinical studies of fluvoxamine in patients with COVID-19 be suppressed by the US medical establishment as they have done for hydroxychloroquine?

This is likely to happen as well to, at a minimum, cause the information from ongoing and planned studies to be less than striking, to discourage further interest. This is how they sideline many great ideas, by corrupting the early pilot studies that are done specifically for the reason of assessing the magnitude of benefits and the likelihood that a large expensive trial will pay off. If the preliminary studies fail to show a positive benefit with small numbers of patients, this will be taken to mean the benefits might be marginal and not worth a large investment, and the idea will be killed then and there. This has been done again and again in all areas of medicine.